{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:05:33Z","timestamp":1790309133516,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Health Technology Assessment Programme (GB)","award":["14\/222\/02"],"award-info":[{"award-number":["14\/222\/02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12888-017-1393-0","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T13:15:11Z","timestamp":1498482911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-2199","authenticated-orcid":false,"given":"L.","family":"Marwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dietch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Attenburrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"McAllister-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Cleare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095\u2013105.","journal-title":"JAMA"},{"key":"1393_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.184.5.386","volume":"184","author":"TB Ust\u00fcn","year":"2004","unstructured":"Ust\u00fcn TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. Br J Psychiatry J Ment Sci. 2004;184:386\u201392.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"1393_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol Oxf Engl. 2015;29:459\u2013525.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"1393_CR4","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"1393_CR5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"1393_CR6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jad.2014.05.013","volume":"166","author":"SC Wooderson","year":"2014","unstructured":"Wooderson SC, Fekadu A, Markopoulou K, Rane LJ, Poon L, Juruena MF, et al. Long-term symptomatic and functional outcome following an intensive inpatient multidisciplinary intervention for treatment-resistant affective disorders. J Affect Disord. 2014;166:334\u201342.","journal-title":"J Affect Disord"},{"key":"1393_CR7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000219922.19305.08","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006;26:250\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"1393_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","volume":"116","author":"A Fekadu","year":"2009","unstructured":"Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4\u201311.","journal-title":"J Affect Disord"},{"key":"1393_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-244X-11-42","volume":"11","author":"AG Wade","year":"2011","unstructured":"Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in major depressive disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;11:42.","journal-title":"BMC Psychiatry"},{"key":"1393_CR10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4088\/JCP.v59n0305","volume":"59","author":"RL Rudolph","year":"1998","unstructured":"Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59:116\u201322.","journal-title":"J Clin Psychiatry."},{"key":"1393_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v63n0410","volume":"63","author":"WJ Burke","year":"2002","unstructured":"Burke WJ, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1393_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","volume":"255","author":"M Adli","year":"2005","unstructured":"Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium\u2013dose treatment has failed? Eur Arch Psychiatry Clin Neurosci. 2005;255:387\u2013400.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1393_CR13","first-page":"71","volume":"25","author":"BE Dornseif","year":"1989","unstructured":"Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25:71\u20139.","journal-title":"Psychopharmacol Bull"},{"key":"1393_CR14","doi-asserted-by":"crossref","unstructured":"Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 2002;161:143\u201351.","DOI":"10.1007\/s00213-002-0999-0"},{"key":"1393_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004850-200105000-00002","volume":"16","author":"E Schweizer","year":"2001","unstructured":"Schweizer E, Rynn M, Mandos LA, Demartinis N, Garc\u00eda-Espa\u00f1a F, Rickels K. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol. 2001;16:137\u201343.","journal-title":"Int Clin Psychopharmacol"},{"key":"1393_CR16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","volume":"168","author":"AJ Rush","year":"2011","unstructured":"Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168:689\u2013701.","journal-title":"Am J Psychiatry"},{"key":"1393_CR17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1176\/foc.8.4.foc570","volume":"8","author":"JC Nelson","year":"2010","unstructured":"Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Focus. 2010;8:570\u201382.","journal-title":"Focus"},{"key":"1393_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40263-014-0152-8","volume":"28","author":"M Bauer","year":"2014","unstructured":"Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28:331\u201342.","journal-title":"CNS Drugs"},{"key":"1393_CR19","unstructured":"NICE. Depression in adults: recognition and management (Updated Edition). NICE Clin Guidel No 90. 2009. https:\/\/www.nice.org.uk\/guidance\/cg90\/chapter\/1-Guidance ."},{"key":"1393_CR20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2013.05.079","volume":"151","author":"M Bauer","year":"2013","unstructured":"Bauer M, Dell\u2019osso L, Kasper S, Pitchot W, Dencker Vansvik E, K\u00f6hler J, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 2013;151:209\u201319.","journal-title":"J Affect Disord"},{"key":"1393_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","volume":"23","author":"J-P Dor\u00e9e","year":"2007","unstructured":"Dor\u00e9e J-P, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin. 2007;23:333\u201341.","journal-title":"Curr Med Res Opin"},{"key":"1393_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","volume":"14","author":"M Bauer","year":"2013","unstructured":"Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, M\u00f6ller H-J, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2013;14:334\u201385.","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"key":"1393_CR23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","volume":"70","author":"M Bauer","year":"2009","unstructured":"Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540\u20139.","journal-title":"J Clin Psychiatry."},{"key":"1393_CR24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/YIC.0000000000000011","volume":"29","author":"M Bauer","year":"2014","unstructured":"Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, et al. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014;29:16\u201325.","journal-title":"Int Clin Psychopharmacol"},{"key":"1393_CR25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","volume":"13","author":"N El-Khalili","year":"2010","unstructured":"El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917\u201332.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1393_CR26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001403","volume":"10","author":"GI Spielmans","year":"2013","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10:e1001403.","journal-title":"PLoS Med"},{"key":"1393_CR27","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","volume":"76","author":"X Zhou","year":"2015","unstructured":"Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76:e487\u201398.","journal-title":"J Clin Psychiatry."},{"key":"1393_CR28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200.","journal-title":"Ann Intern Med"},{"key":"1393_CR29","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Association; 2013. http:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890425596 . Accessed 23 Nov 2016.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1393_CR30","unstructured":"Sheehan DV, Lecrubier Y, Harnett K, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22\u201333."},{"key":"1393_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1393_CR32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.08m04309","volume":"70","author":"A Fekadu","year":"2009","unstructured":"Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70:177\u201384.","journal-title":"J Clin Psychiatry."},{"key":"1393_CR33","volume-title":"The Maudsley prescribing guidelines in psychiatry, 12th Edition","author":"D Taylor","year":"2015","unstructured":"Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry, 12th Edition. Wiley-Blackwell; 2015."},{"key":"1393_CR34","unstructured":"Joint Formulary Committee. British National Formulary. 70th ed. London: BMJ Group and Pharmaceutical Press; 2015."},{"key":"1393_CR35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"1393_CR36","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global Impressions scale. Psychiatry Edgmont. 2007;4:28\u201337.","journal-title":"Psychiatry Edgmont"},{"key":"1393_CR37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"1393_CR38","unstructured":"Brooks R, Rabin R, De Charro F. The measurement and valuation of health status using EQ-5D: a European perspective: evidence from the EuroQol BIOMED research Programme. Springer Science & Business Media; 2013. http:\/\/www.springer.com\/gb\/book\/9781402012143 . Accessed 14 Feb 2017."},{"key":"1393_CR39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JM. The work and social Adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461\u20134.","journal-title":"Br J Psychiatry"},{"key":"1393_CR40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jad.2008.11.004","volume":"116","author":"J Clatworthy","year":"2009","unstructured":"Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R. Understanding medication non-adherence in bipolar disorders using a necessity-concerns framework. J Affect Disord. 2009;116:51\u20135.","journal-title":"J Affect Disord"},{"key":"1393_CR41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","volume":"12","author":"SR Wisniewski","year":"2006","unstructured":"Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA, Investigators STARD. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71\u20139.","journal-title":"J Psychiatr Pract"},{"key":"1393_CR42","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.1192\/bjp.177.39.s28","volume":"177","author":"D Chisholm","year":"2000","unstructured":"Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Wijngaarden BV. Client socio-demographic and service Receipt inventory - European version : development of an instrument for international research. Br J Psychiatry. 2000;177:s28\u201333.","journal-title":"Br J Psychiatry"},{"key":"1393_CR43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","volume":"26","author":"AJ Rush","year":"1996","unstructured":"Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477\u201386.","journal-title":"Psychol Med"},{"key":"1393_CR44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pmh.34","volume":"2","author":"S Germans","year":"2008","unstructured":"Germans S, Van Heck GL, Moran P, Hodiamont PPG. The self-report standardized Assessment of personality-abbreviated scale: preliminary results of a brief screening test for personality disorders. Personal Ment Health. 2008;2:70\u20136.","journal-title":"Personal Ment Health"},{"key":"1393_CR45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2010.01.004","volume":"124","author":"L Forty","year":"2010","unstructured":"Forty L, Kelly M, Jones L, Jones I, Barnes E, Caesar S, et al. Reducing the hypomania checklist (HCL-32) to a 16-item version. J Affect Disord. 2010;124:351\u20136.","journal-title":"J Affect Disord"},{"key":"1393_CR46","doi-asserted-by":"crossref","unstructured":"Harrison J. THINC-it: what is it? European Neuropsychopharmacology; 2016. p. Page S759.","DOI":"10.1016\/S0924-977X(16)31925-3"},{"key":"1393_CR47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/sim.1981","volume":"24","author":"IR White","year":"2005","unstructured":"White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med. 2005;24:993\u20131007.","journal-title":"Stat Med"},{"key":"1393_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"1393_CR49","doi-asserted-by":"crossref","unstructured":"White IR, Horton NJ, Carpenter J, Pocock SJ, others. Strategy for intention to treat analysis in randomised trials with missing outcome data Bmj 2011;342:d40.","DOI":"10.1136\/bmj.d40"},{"key":"1393_CR50","unstructured":"National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical practice guideline No 23. Lond NICE. 2004."},{"key":"1393_CR51","doi-asserted-by":"crossref","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.","journal-title":"BMJ"},{"key":"1393_CR52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2215-0366(15)00450-2","volume":"3","author":"JR Geddes","year":"2016","unstructured":"Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2\u2008\u00d7\u20082 factorial randomised trial. Lancet Psychiatry. 2016;3:31\u20139.","journal-title":"Lancet Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:10:24Z","timestamp":1719274224000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-017-1393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1186\/s12888-017-1393-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]},"article-number":"231"}}